Pfizer (PFE) Shares are Down -0.46%

Pfizer (PFE) has been under a strong bear grip, hence the stock is down -5.41% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 0.2% in the past 1 week. The 4-week change in the price of the stock is -5.61% and the stock has fallen -0.46% in the past 1 week.

For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 1.3% and the fifty day Moving Average is 1.55%. Pfizer Inc. is up 1.44% in the last three month period. Year-to-Date the stock performance stands at 10.84%.

Pfizer (PFE) : 12 Wall Street analysts covering Pfizer (PFE) believe that the average level the stock could reach for the short term is $39.58. The maximum price target given is $54 and the minimum target for short term is around $33, hence the standard deviation is calculated at $5.62.


Pfizer (NYSE:PFE): stock turned positive on Friday. Though the stock opened at $34.8, the bulls momentum made the stock top out at $35.1 level for the day. The stock recorded a low of $34.66 and closed the trading day at $34.82, in the green by 0.14%. The total traded volume for the day was 18,771,960. The stock had closed at $34.77 in the previous days trading.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin and Enbrel, among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP), Global Vaccines, Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing, registering and commercializing medications in therapeutic areas, such as inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases and womens/mens health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira, Inc.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.